Testing of Rx100 has demonstrated its unique properties in comparison to other drug candidates in the pipeline. Of significance is the fact that Rx100: a) is a small molecule, b) is essentially nontoxic at therapeutic doses, c) has a long shelf life, d) is nonimmunogenic, e) and provides effective treatment of ARS when administered up to 72 hours after exposure to lethal, whole-body radiation.
Dr. W. Shannon McCool, RxBio's CEO, points out that: "Rx100 is unique among radioprotectants / radiomitigators in that it boosts natural mechanisms that promote and sustain cell survival in almost every cell type and at the same time inhibits the cascade leading to programmed cell death (apoptosis). Thus, Rx100 augments the good and shuts down the bad. While other products shut down essential cellular signaling mechanisms involved in radiation-induced cellular injury and tend to lack specificity and/or may be toxic, Rx100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival and antiapoptosis. Among its actions, Rx100 protects critical stem cells. Rx100 can be formulated for a wide range of patient types – from infants to the elderly – and can be administered either orally or subcutaneously."
In addition, Dr. Gabor Tigyi, RxBio's CSO, comments that: "Rx100 is a potent protector of the GI tract. This drug provides significant protection to the gut from radiation as well as other toxic substances such as cholera toxin. Among its actions, Rx100 maintains the mucosal barrier of the GI tract. It prevents severe diarrhea and the entry of bacterial toxins into the blood stream – both potentially severe side effects." RxBio has recently presented it's initial NHP data at the BARDA meeting that took place in January, 2011, in Washington. Th
|SOURCE RxBio, Inc.|
Copyright©2010 PR Newswire.
All rights reserved